ArticleJournal of neurology2014
Long-term follow-up of 62 patients with myositis.
Article in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Direct and indirect costs of idiopathic inflammatory myopathies in adults: A systematic review.PloS one · 2024Pooled it
- The health-related quality of life, mental health and mental illnesses of patients with inclusion body myositis (IBM): results of a mixed methods systematic review.Orphanet journal of rare diseases · 2022Pooled it
- Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review.PloS one · 2016Pooled it
- High-intensity resistance training in patients with myositis - 1-year follow-up on a randomised controlled trial.Rheumatology international · 2025Trial
- High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial.Rheumatology international · 2024Trial
- Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.Rheumatology (Oxford, England) · 2021Trial
- Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study.Clinical rheumatology · 2026Article
- Emerging therapies in idiopathic inflammatory myopathies.Journal of neuromuscular diseases · 2026Review
- Clinical characteristics and risk factors associated with objective flares in patients with dermatomyositis.Seminars in arthritis and rheumatism · 2026Article
- Sit to stand and timed up and go in idiopathic inflammatory myopathies.Scientific reports · 2025Observational
- Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.European journal of neurology · 2025Article
- Utilization of Rehabilitation Services After Idiopathic Inflammatory Myopathy Diagnosis: A Retrospective Cohort Assessment in the United States.The Journal of rheumatology · 2025Article
- Barriers and facilitators to exercise in people with idiopathic inflammatory myopathies: a qualitative study.BMC rheumatology · 2025Article
- Idiopathic Inflammatory Myopathies: Recent Evidence Linking Pathogenesis and Clinical Features.International journal of molecular sciences · 2025Review
- Disease characteristics and medications use in idiopathic inflammatory myopathy: a multi-centre prospective observational study of decentralized remote vs. traditional clinic enrolment.Rheumatology (Oxford, England) · 2025Observational
- Article
- Patient-reported outcome for physical function in idiopathic inflammatory myopathy.Rheumatology (Oxford, England) · 2025Observational
- Pathogenic role and clinical significance of neutrophils and neutrophil extracellular traps in idiopathic inflammatory myopathies.Clinical and experimental medicine · 2024Review
- The Role of Exercise to Improve Physiological, Physical and Psychological Health Outcome in Idiopathic Inflammatory Myopathies (IIM).Journal of inflammation research · 2024Review
- Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey.Rheumatology advances in practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work is to evaluate disease-related mortality and the course of the disease including functional outcome and quality of life. We did a follow-up study on a large prospective cohort of 62 patients with subacute-onset idiopathic inflammatory myopathy (IIM) (dermatomyositis (n = 24), nonspecific myositis (n = 34), necrotizing autoimmune myopathy (n = 4)) after treatment with corticosteroids only (randomized controlled trial comparing daily high-dosage prednisone with pulse therapy of dexamethasone). Development of connective tissue disease (CTD) or malignancy, disease course and mortality, functional outcome and quality of life were evaluated. After a mean follow-up of 3 years (SD 1.5), 22 % had developed a CTD and 17 % a malignancy. Disease-related mortality was 15 %. A monophasic disease course was found in 27 %. Most patients had a chronic (35 %) or polyphasic disease (35 %) course and experienced single or multiple relapses. Sixteen patients (33 %) were off medication after a mean of 1 year of treatment. Disability scores improved particularly in the first 18 months. At follow-up, 68 % still perceived disabilities. Quality of life scores as measured by the short-form (SF)-36 improved in the first 18 months. After 18 months, scores remained stable during the next years of follow-up and remained low compared to a normal population. (1) Two-thirds of the patients with an IIM have a polyphasic or chronic disease course and need maintenance treatment. (2) The impact on functional outcome and quality of life is considerable and does not improve further after 18 months.
Indexed as
Identifiers
24658663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.